147959-19-1 Usage
General Description
(S)-Tert-butyl 2,2-dimethyl-4-(2-oxoethyl)oxazolidine-3-carboxylate is a chemical compound that belongs to the class of oxazolidine carboxylates. It is a stable and versatile molecule that is commonly used for various applications in organic synthesis. (S)-TERT-BUTYL 2,2-DIMETHYL-4-(2-OXOETHYL)OXAZOLIDINE-3-CARBOXYLATE is known for its ability to act as a chiral building block, making it useful in the synthesis of complex organic molecules and pharmaceutical products. It is also used in the production of agrochemicals, dyes, and other specialty chemicals. Additionally, this compound has potential applications in the field of materials science, including as a precursor for the synthesis of polymers and advanced materials. Overall, (S)-Tert-butyl 2,2-dimethyl-4-(2-oxoethyl)oxazolidine-3-carboxylate is a valuable compound with a wide range of potential uses across various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 147959-19-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,7,9,5 and 9 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 147959-19:
(8*1)+(7*4)+(6*7)+(5*9)+(4*5)+(3*9)+(2*1)+(1*9)=181
181 % 10 = 1
So 147959-19-1 is a valid CAS Registry Number.
147959-19-1Relevant articles and documents
Synthesis of sphingosine analogues: Stereoselective synthesis of 3- deoxysphingosine and cis-isomers
Kawate, Tomohiko,Fukuta, Natsuko,Nishida, Atsushi,Nakagawa, Masako
, p. 2116 - 2118 (1997)
Both enantiomers of 3-deoxysphingosine as well as their cis-isomers were synthesized stereoselectively from L- and D-serine.
NOVEL QUINOLINE-SUBSTITUTED COMPOUND
-
, (2016/10/10)
An object to be achieved by the present invention is to provide a novel compound having EGFR inhibitory effects and cell growth inhibitory effects, as well as a medication useful for the prevention and/or treatment of cancer based on the EGFR inhibitory effects. The present invention provides a compound represented by Formula (I) below, or a salt thereof.
FACTOR XIa INHIBITORS
-
Page/Page column 71, (2015/12/09)
The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.